Hangzhou Coco Healthcare Products Co (301009) Fair Value & Analysis
Consumer Defensive · CN · Market cap 2.4B CNY
Fair value as of: Jul 9, 2026
From 22 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥3.56 to ¥2.79 (−21.6%) since Jun 24, 2026. Share price +11.3% over the past month.
A solid business, but screening 70% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥3.49). The favourable scenario is already priced in.
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥6.78 – ¥33.97 · fair‑value band ¥2.09 – ¥3.49 · the ¥9.26 price screens above the ¥2.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Hangzhou Coco Healthcare Products Co (301009) currently trades at ¥9.26, while our model-based Fair Value estimate is ¥2.79, implying the stock looks roughly 69.9% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Hangzhou Coco Healthcare Products Co generated revenue of 1.2B CNY at a net margin of 1.7%. Revenue grew 4.0% year over year. It earns a return on equity of 1.5%. The balance sheet holds a net cash position of 505M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥2.09 (bear case) to ¥3.49 (bull case); at ¥9.26, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -70%, 301009 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: DCF Models (¥6.11) versus Earnings-Based (¥1.37). Highest evidence: Residual Income (76).
Notify me when 301009 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hangzhou Coco Healthcare Products Co.,Ltd. engages in the research, development, production, and sale of baby care, adult incontinence, and pet hygiene products in China and internationally.
Full company description
Hangzhou Coco Healthcare Products Co.,Ltd. engages in the research, development, production, and sale of baby care, adult incontinence, and pet hygiene products in China and internationally. It offers adult incontinence products, including adult diapers, adult pull-up pants, nursing pads, maternity towels, menstrual pants, absorbent towels, and other products, as well as feminine, cleaning, family, and medical care products. The company was formerly known as Hangzhou Qiaozi Paper Industry Co.,Ltd. and changed its name to Hangzhou Coco Healthcare Products Co.,Ltd. in December 2011. Hangzhou Coco Healthcare Products Co.,Ltd. was incorporated in 2001 and is headquartered in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hangzhou Coco Healthcare Products Co reported revenue of ¥1.2B in FY2025 versus ¥1.2B in FY2021, a compound −0.8%/yr. Reported net income was ¥36.1M in FY2025, compounding −2.4%/yr from FY2021.
301009 screens 70% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Hangzhou Coco Healthcare Products Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Hangzhou Coco Healthcare Products Co (301009) overvalued or undervalued?
What is the fair value of 301009?
What is the quality score of 301009?
What is the revenue of Hangzhou Coco Healthcare Products Co (301009)?
What is the net profit margin of 301009?
Does Hangzhou Coco Healthcare Products Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hangzhou Coco Healthcare Products Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.